ClinicalTrials.gg
RecruitingNCT07941128Updated Nov 17, 2026

Pragmatic AI-Assisted Lung Cancer Translational Study

An interventional study of Revision of Medical Records in Lung Cancer, Artificial Intelligence (AI) and Large Language Model, sponsored by Sir Run Run Shaw Hospital. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2026, registered Nov 2026).
  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 845 studies in Lung Neoplasms with a site in China — 372 open to participants now, 419 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
197th of 586
150 · median 90
Started
2026
with 89 others
No phase
213 of 845
92 open now
Primary completion
2026-11
later than 183 of 418 live
Registered
845th of 845
by date

Among the 845 studies in Lung Neoplasms with a site in China, this one is the 197th largest by planned enrollment of the 586 interventional ones that give a count, is one of 90 that started in 2026, is one of 213 with no phase, reaches primary completion later than 183 of the 418 other live ones, and was the 845th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

372 of the 845 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

366 more — sign in →

All 372 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 845 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to learn whether an artificial intelligence (AI) tool helps healthcare providers write and revise medical notes and check medical orders. This prospective study compares routine documentation without AI to documentation with AI assistance. The AI tool helps draft notes and review orders, but it does not make treatment decisions. Researchers will compare the quality of the notes, the time spent writing them, and the number of order errors between the two methods. The results will help hospitals decide if AI can improve daily clinical workflows.

03

Conditions studied

  • Lung Cancer
  • Artificial Intelligence (AI)
  • Large Language Model

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers:

  • Junior physicians (less than 2 years of clinical experience) working in the departments of respiratory medicine, thoracic surgery, or oncology at the participating center.
  • Currently undergoing standardized residency training.
  • Primarily responsible for writing clinical notes and placing/verifying non-critical medical or surgical orders in routine practice.

Patients:

  • Adults aged 18 years or older with a confirmed diagnosis of lung cancer.
  • Managed by participating physicians during the study period.
  • Received complete diagnostic evaluation and treatment at the participating center.

Exclusion criteria

Exclusion Criteria:

Providers:

  • Interns, students, or auxiliary staff who are not directly responsible for writing clinical notes.
  • Physicians who refuse to use the AI tool or are unable to complete the study workflow.
  • Patients whose records are managed by non-participating physicians.

Patients:

  • Non-standard admissions that do not follow standard inpatient documentation workflows, or cases where note quality or order accuracy cannot be evaluated.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Self-Controlled Group:Sequential manual and AI-Assisted

    This study uses a before-and-after self-controlled design; therefore, it is a single-arm study.

    Other: Revision of Medical Records

Interventions

  • OtherRevision of Medical Records

    The intervention is an Artificial Intelligence (AI)-assisted clinical documentation tool integrated into the daily workflow of healthcare providers. The AI system assists providers by generating and revising clinical notes and double-checking medical orders. The tool functions solely as a documentation and verification aid; it does not make or alter clinical treatment decisions. This intervention is evaluated against standard, routine documentation practices to assess its impact on workflow efficiency, note quality, and order accuracy.

06

What researchers measure

Primary outcomes

  1. Document quality score

    The PDQI-9 (The 9-Item Physician Documentation Quality Instrument) is used as the baseline scale. Each item on the baseline scale is scored on a scale of 1 to 5, with 1 being the worst and 5 being the best.

    Time frame: Within one week after completing all medical records

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to ethical restrictions and to protect patient privacy and confidentiality.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.

Of 868 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 3 months is below that.

Counting every sponsor, half of 919 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 17, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941128
Responsible party
Xiaonan Sun (Professor, Sir Run Run Shaw Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Aug 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Minghao Hu, M.D.
Contact
1171233201@qq.com
+8613396366466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion